Plus Therapeutics Income Statement (2010-2025) | PSTV

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Mar2021	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025
Revenue & cost
Revenue (Quarter)							0.07M	0.13M	0.51M	1.90M	4.40M	1.31M	1.68M	1.28M	1.46M	1.41M	1.06M	1.39M	1.40M	1.37M
Cost of Revenue (Quarter)
Gross Profit (Quarter)
Operating items
Amortization - Intangibles (Quarter)
Research & Development (Quarter)	1.13M	1.11M	1.49M		1.78M	2.83M	2.94M	2.14M	2.98M	1.42M	2.49M	0.07M	2.76M	2.77M	2.86M	2.19M	1.76M	1.25M	2.44M	2.94M
Selling, General & Administrative (Quarter)	1.35M	1.47M	1.99M		2.14M	2.29M	2.22M	3.58M	2.25M	1.92M	2.00M	2.38M	2.21M	2.20M	2.40M	3.13M	2.84M	1.68M	3.44M	4.17M
Other Operating Expenses (Quarter)			-0.02M					0.02M	-0.00M			2.72M
Operating Expenses (Quarter)	2.48M	2.58M	3.50M		3.93M	5.12M	5.17M	5.72M	5.23M	3.34M	4.49M	5.17M	4.98M	4.98M	5.25M	5.31M	4.59M	2.93M	5.88M	7.11M
Operating Income (Quarter)	-2.48M	-2.58M	-3.50M		-3.93M	-5.12M	-5.09M	-5.57M	-4.72M	-1.49M	-3.25M	-3.86M	-3.30M	-3.70M	-3.80M	-3.90M	-3.54M	-1.54M	-4.48M	-5.74M
EBIT (Quarter)	-2.48M	-2.58M	-3.50M		-3.93M	-5.12M	-5.09M	-5.57M	-4.72M	-1.49M	-3.25M	-3.86M	-3.30M	-3.70M	-3.80M	-3.90M	-3.54M	-1.54M	-4.48M	-5.74M
Non-operating items
Interest & Investment Income (Quarter)	0.00M	0.00M	0.01M		0.01M	0.02M	0.05M	0.07M	0.05M	0.12M	0.12M	0.11M	0.07M	0.07M	0.08M	0.05M	0.00M	0.03M	0.06M	0.03M
Other Non Operating Income (Quarter)	0.00M		0.00M		0.00M
Non Operating Income (Quarter)	-0.24M	-0.23M	-0.23M		-0.19M	-0.16M	-0.12M	-0.09M	-0.08M	0.01M	0.03M	0.05M	0.04M	0.76M	0.93M	-0.00M	-13.87M	6.69M	0.06M	0.03M
Net income details
EBT (Quarter)	-2.72M	-2.80M	-3.73M		-4.12M	-5.30M	-5.25M	-5.61M	-4.77M	-1.48M	-3.22M	-3.81M	-3.26M	-3.66M	-3.78M	-3.90M	-4.08M	-1.51M	-4.42M	-5.71M
Profit After Tax (Quarter)	-2.72M	-2.80M	-3.72M		-4.12M	-5.28M	-5.22M	-5.66M	-4.80M	-1.48M	-3.22M	-3.81M	-3.26M	-2.94M	-2.87M	-3.90M	-17.40M	5.15M	-4.42M	-5.70M
Equity Income (Quarter)
Income from Continuing Operations (Quarter)	-2.72M	-2.80M	-3.73M		-4.12M	-5.30M	-5.25M	-5.61M	-4.77M	-1.48M	-3.22M	-3.81M	-3.26M	-3.66M	-3.78M	-3.90M	-4.08M	-1.51M	-4.42M	-5.71M
Consolidated Net Income (Quarter)	-2.72M	-2.80M	-3.73M		-4.12M	-5.30M	-5.25M	-5.61M	-4.77M	-1.48M	-3.22M	-3.81M	-3.26M	-3.66M	-3.78M	-3.90M	-4.08M	-1.51M	-4.42M	-5.71M
Income towards Parent Company (Quarter)	-2.72M	-2.80M	-3.73M		-4.12M	-5.30M	-5.25M	-5.61M	-4.77M	-1.48M	-3.22M	-3.81M	-3.26M	-3.66M	-3.78M	-3.90M	-4.08M	-1.51M	-4.42M	-5.71M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)	-2.72M	-2.80M	-3.73M		-4.12M	-5.30M	-5.25M	-5.61M	-4.77M	-1.48M	-3.22M	-3.81M	-3.26M	-3.66M	-3.78M	-3.90M	-4.08M	-1.51M	-4.42M	-5.71M
Additional items
EPS (Basic) (Quarter)	-0.33	-0.25	-0.28		-0.19	-3.56	-2.85	-2.36	-2.07	-0.59	-1.00	-0.70	-0.75	-0.45	-0.37	-0.49	-1.19	0.02	-0.04	-0.07
EPS (Weighted Average and Diluted) (Quarter)		-0.25	-0.28		-0.19	-3.56	-2.85	-2.36	-2.07	-0.59	-1.00	-0.70	-0.75	-0.71	-0.37	-0.67	-1.19	-0.01	-0.04	-0.07
Shares Outstanding (Weighted Average) (Quarter)	8.27M	2.14M	10.96M	12.09M	2.14M	1.46M	2.14M	1.75M	2.14M	2.51M	3.23M	3.14M	4.32M	5.41M	6.23M	6.64M	134.71M	24.42M	107.43M	77.80M
Shares Outstanding (Diluted Average) (Quarter)		11.30M	13.26M	12.09M	21.51M	1.48M	1.83M	1.75M	2.32M	2.51M	3.23M	3.14M	4.32M	7.53M	7.86M	7.70M	14.57M	24.42M	57.85M	77.80M
EBITDA (Quarter)	-2.48M	-2.58M	-3.50M		-3.93M	-5.12M	-5.09M	-5.57M	-4.72M	-1.49M	-3.25M	-3.86M	-3.30M	-3.70M	-3.80M	-3.90M	-3.54M	-1.54M	-4.48M	-5.74M
Interest Expenses (Quarter)	0.25M	0.23M	0.23M		0.20M	0.20M	0.20M	0.11M	0.10M	0.11M	0.09M	0.06M	0.03M	0.03M	0.06M	0.06M	0.55M

Research Tools

Plus Therapeutics Income Statement (2010-2025) | PSTV

Create an account

Sign In

Reset Password